These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 2672587)

  • 1. [Fibrin/fibrinogen degradation products in ischemic heart disease].
    Ena IaM; Polishko VK; Semina AG
    Vrach Delo; 1989 May; (5):9-14. PubMed ID: 2672587
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasma fibrinogen, fibrinolytic activity and serum fibrinogen/fibrin degradation products in ischaemic heart disease.
    Dube B; Somani PN; Tripathi GK; Dube RK; Bhattacharya SK
    J Assoc Physicians India; 1985 Dec; 33(12):784-5, 787. PubMed ID: 3837002
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical value of studying fibrinogen degradation products in patients with ischemic heart disease].
    Ikonnikova EI; Katkova NB; Filippova SB
    Klin Med (Mosk); 1989 May; 67(5):35-6. PubMed ID: 2770207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Changes in the content of fibrinogen and its high-molecular derivatives as affected by the physical training of ischemic heart disease patients].
    Dudaev VA; Diukov IV; Borodkin VV
    Ter Arkh; 1986; 58(12):62-7. PubMed ID: 3824217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the hemorheological factors in ischemic heart disease and cerebrovascular disorders.
    Fukuda I; Yoshida T; Yoritsune H; Kiso T; Konishi S; Kawasaki T; Mozai T
    Bull Osaka Med Sch; 1978 Oct; 24(2):83-91. PubMed ID: 757138
    [No Abstract]   [Full Text] [Related]  

  • 6. [Hemostasis in ischemic heart disease patients undergoing hyperbaric oxygenation].
    Goliakov VN; Eroshina VA; Zimin IuV; Semiletova VI
    Klin Med (Mosk); 1986 Feb; 64(2):92-5. PubMed ID: 3702304
    [No Abstract]   [Full Text] [Related]  

  • 7. [Fibrinogen degradation products in cardiac surgery].
    Terrier E; Baillet M; Ayed K; Jaulmes B
    Pathol Biol (Paris); 1974 Nov; 22 suppl():60-5. PubMed ID: 4620098
    [No Abstract]   [Full Text] [Related]  

  • 8. [Quantitative immunoenzyme method for determining fibrin-fibrinogen degradation products in the blood].
    Ermolin GA; Liusov VA; Panchenko EP
    Lab Delo; 1984; (1):11-5. PubMed ID: 6199554
    [No Abstract]   [Full Text] [Related]  

  • 9. [Fluctuation of plasma levels of fibrinogen degradation products, fibrin degradation products and total fibrin/fibrinogen degradation products in patients with DIC].
    Isogai N; Kuroso K; Fujimaki M; Yorifuji H; Fukutake K
    Rinsho Byori; 1993 Dec; 41(12):1349-52. PubMed ID: 8295346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Serum levels of fibrinogen degradation products in patients with hepatic cirrhosis].
    Cristani A; Cioni G; Minetto G; Di Pancrazio L; Anderlini D; Grandi S; Vezzelli C; Zirilli E; Zeneroli ML; Ventura E
    Recenti Prog Med; 1987 Oct; 78(10):431-3. PubMed ID: 3432720
    [No Abstract]   [Full Text] [Related]  

  • 11. A study of soluble fibrin monomer complexes (SFMC) and plasma fibrinogen in acute myocardial infarction.
    Jain SM; Trivedi S
    Indian J Chest Dis Allied Sci; 1984; 26(2):98-103. PubMed ID: 6530267
    [No Abstract]   [Full Text] [Related]  

  • 12. [The significance of plasma D-dimer contents in patients with coronary heart disease].
    Huang C; Xu M; Zhao Y
    Hunan Yi Ke Da Xue Xue Bao; 1997; 22(6):551-2. PubMed ID: 10073007
    [No Abstract]   [Full Text] [Related]  

  • 13. [Determination of fibrin (fibrinogen) degradation products in urine].
    Andreenko GV; Podorol'skaia LV
    Lab Delo; 1983; (4):35-8. PubMed ID: 6191081
    [No Abstract]   [Full Text] [Related]  

  • 14. Association of European population levels of thrombotic and inflammatory factors with risk of coronary heart disease: the MONICA Optional Haemostasis Study.
    Yarnell J; McCrum E; Rumley A; Patterson C; Salomaa V; Lowe G; Evans A
    Eur Heart J; 2005 Feb; 26(4):332-42; discussion 317-8. PubMed ID: 15618045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of D-Dimers and fibrinogen plasma determination in patients with polyvascular disease.
    Bosevski M; Kostoska S; Tosev S; Borozanov V
    Angiol Sosud Khir; 2006; 12(2):9-15. PubMed ID: 17053757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Catabolism of purified rat fibrin(ogen) plasmin degradation products in rats.
    Nieuwenhuizen W; Emeis JJ; Vermond A
    Thromb Haemost; 1982 Aug; 48(1):59-61. PubMed ID: 7135343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific identification of urinary fibrinogen, fibrinogen degradation products, and cross-linked fibrin degradation products in renal diseases and after renal allotransplantation.
    Scott WL; Francis CW; Knutson DW; Marder VJ
    J Lab Clin Med; 1986 Jun; 107(6):534-43. PubMed ID: 3519810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structures of fragments D and double-D from fibrinogen and fibrin.
    Doolittle RF; Spraggon G; Everse SJ
    Thromb Haemost; 1999 Aug; 82(2):271-6. PubMed ID: 10605713
    [No Abstract]   [Full Text] [Related]  

  • 19. Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease.
    Lowe GD; Rumley A; McMahon AD; Ford I; O'Reilly DS; Packard CJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1529-34. PubMed ID: 15205218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Kinetics of fibrin lysis by plasmin: inhibition by fibrin degradation products].
    Zhitkova IuV; Aĭsina RB; Varfolomeev SD
    Bioorg Khim; 1996 Dec; 22(12):911-5. PubMed ID: 9054342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.